ErVimmune

Designs immunotherapies based on the identification of unconventional tumour antigens derived from human endogenous retroviruses (HERVs). Using an approach combining artificial intelligence, proteomics and immunology, it is developing therapeutic vaccines and cell-based therapies to target cold tumours. Its lead candidate is a universal vaccine against triple-negative breast cancer and ovarian cancer.